National Health Investors, Inc. <NHI.N>: Wells Fargo cuts target price to $78 from $79
NHI•Related News
Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps
UPB•
Hewlett Packard Enterprise Company <HPE.N>: Deutsche Bank initiates coverage with buy rating and target price $62
HPE•
Medtronic boosts fiscal 2027 forecasts on heart device demand
MDT•
Global bond rout deepens as Japan yield hits key milestone
TLT•
BioCryst to present at Morgan Stanley Global Healthcare Conference
BCRX•